The FDA has approved a test to determine which patients are appropriate for Keytruda as the first-line treatment of metastatic non–small cell lung cancer.
The FDA granted approval to pembrolizumab for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors express programmed death ligand-1 as determined by an FDA–approved test.
Atezolizumab (Tecentriq, Genentech) — the first and only FDA–approved anti–PD-L1 cancer immunotherapy — is intended for patients with urothelial carcinoma who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.
“Tecentriq is a new medicine that can work with the immune system to treat people with a type of bladder cancer that progressed after platinum-based chemotherapy,” Sandra Horning, MD, chief medical officer and head of Global Product Development at Genentech, said in a press release. “We thank the scientists, doctors, patients and their families who made it possible to bring Tecentriq to people with advanced urothelial carcinoma.”
|Read Full Article: FDA Approves Keytruda for First-Line Treatment of PD-L1–Expressing Metastatic NSCLC|